Methods for treating radiation or chemical injury are described that comprise administering to a subject a therapeutically effective amount of adherent stromal cells. Methods of preparing adherent stromal cells and pharmaceutical compositions comprising the cells are also described.

The present invention provides a pharmaceutical composition for delivering palonosetron through the buccal mucosa or sublingual mucosa. The pharmaceutical composition comprises 0.05-35% (w/w) of palonosetron, 40-90% of a film forming agent, 1-10% (w/w) of a plasticizer, 5-25% (w/v) of an adhesive agent, and 0.1-5% of a penetration enhancing agent. A preferred plasticizer is a polysorbate. A preferred adhesive agent is polyvinylpyrrolidone or carboxymethylcellulose. A preferred penetration enhancing agent is peppermint oil or menthol.

The present invention provides novel compounds comprising cannabigerolic acid (CBGA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.

The present invention provides dicyclohexylamine salt of fosaprepitant (fosaprepitant DCHA), a process for preparing fosaprepitant DCHA, and a use of fosaprepitant DCHA in the preparation of pharmaceutically acceptable fosaprepitant dimeglumine with high purity. Fosaprepitant dimeglumine is prepared by treating fosaprepitant DCHA with an acid to form fosaprepitant, followed by adding N-methyl-D-glucamine to fosaprepitant.

The present disclosure relates to cannabinoid-based therapeutics, and their use in treating pain, e.g., chronic pain. The present disclosure also relates to cannabinoid-based therapeutics, and their use in treating opioid addiction.

1-[2-(2,4-dimethylphenylsulphanyl)phenyl)]piperazine exhibits potent activity on SERT, 5-HT.sub.3 and 5-HT.sub.1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.

Methods, compositions, systems, and packaging are disclosed for reducing postoperative nausea and/or vomiting (PONV) in a human patient in need of general anesthesia for surgery. Such methods may include scheduling a surgery for the human patient, and administering to the patient one or more series of prescribed medicines for at least three successive days during a regimen immediately preceding general anesthesia. Compositions may include cholinergic receptor agonists, muscarinic receptor agonists, dopamine receptor agonists, MAO inhibitors, serotonin receptor agonists, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin releasing agents, serotonin-norepinephrine-dopamine reuptake inhibitors, opioids, or analgesics.

An application of a GABA.sub.A receptor allosteric enhancer in medicine. Specifically provided is use of the GABA.sub.A receptor allosteric enhancer shown in formula (I) in preparation of drugs for sedatives, hypnosis, treatment or prevention of anxiety, depression, insomnia, nausea, vomiting, migraine, schizophrenia, convulsions, and ##STR00001##

The present invention provides novel compounds comprising cannabidiolic acid (CBDA) derivatives, including acids and esters, and uses thereof in the treatment of various diseases, disorders, conditions and symptoms.

A bee ingestible composition comprising a bee food base and THC and/or CBD is provided. Also provided are methods of producing honey, honey obtainable by these methods and uses of same.